Treatment of hemorrhagic lupus pneumonitis with plasmapheresis (Q40581242)

21 September 2017

1 reference

title

Treatment of hemorrhagic lupus pneumonitis with plasmapheresis (English)

1 reference

21 September 2017

Erickson RW

1

1 reference

PubMed ID

7839153

21 September 2017

Franklin WA

series ordinal

2

1 reference

PubMed ID

7839153

21 September 2017

Emlen W

series ordinal

3

1 reference

21 September 2017

1 October 1994

1 reference

Seminars in Arthritis and Rheumatism

21 September 2017

1 reference

21 September 2017

24

1 reference

21 September 2017

2

1 reference

21 September 2017

114-123

1 reference

Disseminated immune deposits in lupus erythematosus

21 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980005-8

7 January 2021

Severe, acute pulmonary disease in patients with systemic lupus erythematosus: ten years of experience at the National Institutes of Health

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980005-8

7 January 2021

Acute Alveolar Hemorrhage in Lupus Erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980005-8

7 January 2021

Pulmonary hemorrhage in pediatric patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980005-8

7 January 2021

Systemic lupus erythematosus: a case report with unusual manifestations and favourable outcome after plasmapheresis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980005-8

7 January 2021

Acute Pulmonary Complications in Systemic Lupus Erythematosus: Immunofluorescence and Light Microscopic Study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980005-8

7 January 2021

Immunopathologic features of a patient with glomerulonephritis and pulmonary hemorrhage

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980005-8

7 January 2021

Pleuro-pulmonary manifestations of systemic lupus erythematosus: clinical features of its subgroups. Prognostic and therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980005-8

7 January 2021

Pulmonary hemorrhage and systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980005-8

7 January 2021

Immunopathologic Studies of Pneumonitis in Systemic Lupus Erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980005-8

7 January 2021

Pulmonary alveolar hemorrhage in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980005-8

7 January 2021

Pulmonary hemorrhage in patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980005-8

7 January 2021

Pulmonary hemorrhage complicating systemic lupus erythematosus: role of MR imaging in diagnosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980005-8

7 January 2021

Massive Asphyxiating Pulmonary Hemorrhage and Glomerulonephritis in a 41-Year-Old Woman

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980005-8

7 January 2021

The pulmonary manifestations of systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980005-8

7 January 2021

Immune alveolar hemorrhage

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980005-8

7 January 2021

Synchronization of plasmapheresis and pulse cyclophosphamide in severe systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980005-8

7 January 2021

Plasmapheresis therapy of immunologic disease. Report of nine cases and review of the literature.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980005-8

7 January 2021

Plasmapheresis in the management of acute systemic lupus erythematosus?

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980005-8

7 January 2021

Randomised trial of plasma exchange in mild systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980005-8

7 January 2021

A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980005-8

7 January 2021

Guillain-Barré syndrome in childhood: natural course and efficacy of plasmapheresis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980005-8

7 January 2021

Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. French Cooperative Group on Plasma Exchange in Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980005-8

7 January 2021

Plasmapheresis for severe, unremitting, chronic urticaria

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980005-8

7 January 2021

The effect of combination therapy (steroids, immunosuppressives, and plasmapheresis) on 5 mixed cryoglobulinemia patients with renal, neurologic, and vascular involvement

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980005-8

7 January 2021

Plasmapheresis as sole therapy in a patient with essential mixed cryoglobulinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980005-8

7 January 2021

Infectious complications with plasmapheresis in rapidly progressive glomerulonephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980005-8

7 January 2021

Mortality in therapeutic haemapheresis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980005-8

7 January 2021

Complications of therapeutic plasma exchange.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980005-8

7 January 2021

Plasmapheresis does not increase the risk for infection in immunosuppressed patients with severe lupus nephritis. The Lupus Nephritis Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980005-8

7 January 2021

10.1016/S0049-0172(05)80005-8

Identifiers

DOI

1 reference

21 September 2017

1 reference

PubMed ID

7839153